FDA Approves Three New Dementia Drugs to Slow Disease Progression
Three new medications, aducanumab, lecanemab, and donanemab, have been approved by the FDA to slow biological changes linked to certain types of dementia. These drugs join a range of treatments aimed at improving quality of life, reducing symptoms, and slowing disease progression.
Dementia treatment varies based on its causes and progression. While there's no cure, various approaches can help manage symptoms and enhance overall well-being.
In early stages, non-medication therapies play a significant role. These include cognitive stimulation, physical activity, occupational therapy, music therapy, and psychotherapy for mood symptoms. Medication, often drugs approved for Alzheimer's, can also be used, but non-medication therapies help maintain independence and quality of life.
As dementia progresses, treatments focus on slowing disease progression and reducing symptom severity. This may involve both medication and non-medication therapies, such as psychotherapy, cognitive behavioral therapy, relaxation techniques, and support groups. Other medications manage symptoms, including cholinesterase inhibitors, glutamate regulators, and orexin receptor antagonists.
Complementary treatments like massage, acupuncture, yoga, and therapeutic touch may also help manage discomfort associated with cognitive decline.
Dementia treatment is complex and multifaceted, with no one-size-fits-all solution. The FDA's approval of new medications offers hope, but managing symptoms and improving quality of life remain key goals. A combination of medication and non-medication therapies, tailored to the individual's needs, is often the best approach.
Read also:
- Intestinal Infection Causing Stomach Distress: Signs and Remedies
- What is the expected timing for the flu season in this current year?
- Essential Information on Cushing Syndrome: a Disorder Caused by High Cortisol Levels
- Starting in September, elderly individuals aged 75 years and above will be enrolled in a preventive program for Respiratory Syncytial Virus (RSV).
